142 related articles for article (PubMed ID: 34250423)
1. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.
Williams PM; Forbes T; P Lund S; Cole KD; He HJ; Karlovich C; Paweletz CP; Stetson D; Yee LM; Connors DE; Keating SM; Destenaves B; Cleveland MH; Lau CJ; Barrett JC; Kelloff GJ; McCormack RT
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250423
[TBL] [Abstract][Full Text] [Related]
2. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
[TBL] [Abstract][Full Text] [Related]
3. Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.
Zhao J; Reuther J; Scozzaro K; Hawley M; Metzger E; Emery M; Chen I; Barbosa M; Johnson L; O'Connor A; Washburn M; Hartje L; Reckase E; Johnson V; Zhang Y; Westheimer E; O'Callaghan W; Malani N; Chesh A; Moreau M; Daber R
Mol Diagn Ther; 2023 Nov; 27(6):753-768. PubMed ID: 37632661
[TBL] [Abstract][Full Text] [Related]
4. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
5. Analytical Performance Evaluation of a 523-Gene Circulating Tumor DNA Assay for Next-Generation Sequencing-Based Comprehensive Tumor Profiling in Liquid Biopsy Samples.
Harter J; Buth E; Johaenning J; Battke F; Kopp M; Zelba H; Schulze M; Koedding J; Biskup S
J Mol Diagn; 2024 Jan; 26(1):61-72. PubMed ID: 37865292
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
7. From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis.
Peng R; Zhang R; Horan MP; Zhou L; Chai SY; Pillay N; Tay KH; Badrick T; Li J
Oncologist; 2020 Mar; 25(3):218-228. PubMed ID: 32162803
[TBL] [Abstract][Full Text] [Related]
8. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.
Rothwell DG; Ayub M; Cook N; Thistlethwaite F; Carter L; Dean E; Smith N; Villa S; Dransfield J; Clipson A; White D; Nessa K; Ferdous S; Howell M; Gupta A; Kilerci B; Mohan S; Frese K; Gulati S; Miller C; Jordan A; Eaton H; Hickson N; O'Brien C; Graham D; Kelly C; Aruketty S; Metcalf R; Chiramel J; Tinsley N; Vickers AJ; Kurup R; Frost H; Stevenson J; Southam S; Landers D; Wallace A; Marais R; Hughes AM; Brady G; Dive C; Krebs MG
Nat Med; 2019 May; 25(5):738-743. PubMed ID: 31011204
[TBL] [Abstract][Full Text] [Related]
9. Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J; Ngeow KC; Pek M; Tan KH; Lim JS; Chen H; Ong CK; Lim JQ; Lim ST; Lim CM; Goh BC; Choudhury Y
PLoS One; 2022; 17(4):e0267389. PubMed ID: 35486650
[TBL] [Abstract][Full Text] [Related]
10. Identification of germline cancer predisposition variants during clinical ctDNA testing.
Stout LA; Kassem N; Hunter C; Philips S; Radovich M; Schneider BP
Sci Rep; 2021 Jul; 11(1):13624. PubMed ID: 34211039
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
12. Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers.
Shah AN; Sunderraj A; Finkelman B; See SH; Davis AA; Gerratana L; Wehbe F; Katam N; Mahalingam D; Gradishar WJ; Behdad A; Blanco L; Cristofanilli M
Oncotarget; 2022; 13():273-280. PubMed ID: 35126865
[TBL] [Abstract][Full Text] [Related]
13. Continual Improvement of the Reliability of Next-Generation Sequencing-Based ctDNA Analysis: A Long-Term Comparison of ctDNA Detection in China.
Peng R; Zhang R; Li J
Clin Chem; 2022 Jul; 68(7):940-952. PubMed ID: 35687601
[TBL] [Abstract][Full Text] [Related]
14. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
[TBL] [Abstract][Full Text] [Related]
16. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
Valpione S; Campana L
Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
[TBL] [Abstract][Full Text] [Related]
17. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
[TBL] [Abstract][Full Text] [Related]
18. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
[TBL] [Abstract][Full Text] [Related]
19. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
20. Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA.
Stitz R; Buder A; Silye R; Baumgartner B; Pühringer F; Filipits M; Oberndorfer E; Heitzer E
Exp Mol Pathol; 2021 Dec; 123():104685. PubMed ID: 34560086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
